nodes	percent_of_prediction	percent_of_DWPC	metapath
Nalidixic Acid—Cranial nerve paralysis—Vincristine—lymphatic system cancer	0.0886	0.0886	CcSEcCtD
Nalidixic Acid—Metabolic acidosis—Teniposide—lymphatic system cancer	0.0481	0.0481	CcSEcCtD
Nalidixic Acid—Cranial nerve paralysis—Methotrexate—lymphatic system cancer	0.043	0.043	CcSEcCtD
Nalidixic Acid—Metabolic acidosis—Fludarabine—lymphatic system cancer	0.0423	0.0423	CcSEcCtD
Nalidixic Acid—Blister—Mechlorethamine—lymphatic system cancer	0.0358	0.0358	CcSEcCtD
Nalidixic Acid—Optic neuritis—Fludarabine—lymphatic system cancer	0.0272	0.0272	CcSEcCtD
Nalidixic Acid—Trauma—Bleomycin—lymphatic system cancer	0.0257	0.0257	CcSEcCtD
Nalidixic Acid—Intracranial pressure increased—Carmustine—lymphatic system cancer	0.0256	0.0256	CcSEcCtD
Nalidixic Acid—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0207	0.0207	CcSEcCtD
Nalidixic Acid—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.0196	0.0196	CcSEcCtD
Nalidixic Acid—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0153	0.0153	CcSEcCtD
Nalidixic Acid—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Nalidixic Acid—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Nalidixic Acid—Vertigo—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Nalidixic Acid—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Nalidixic Acid—Injury—Bleomycin—lymphatic system cancer	0.00968	0.00968	CcSEcCtD
Nalidixic Acid—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00927	0.00927	CcSEcCtD
Nalidixic Acid—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0092	0.0092	CcSEcCtD
Nalidixic Acid—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00916	0.00916	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00901	0.00901	CcSEcCtD
Nalidixic Acid—Swelling—Carmustine—lymphatic system cancer	0.0088	0.0088	CcSEcCtD
Nalidixic Acid—Injury—Carmustine—lymphatic system cancer	0.00845	0.00845	CcSEcCtD
Nalidixic Acid—Swelling—Mitoxantrone—lymphatic system cancer	0.00818	0.00818	CcSEcCtD
Nalidixic Acid—Visual impairment—Fludarabine—lymphatic system cancer	0.00809	0.00809	CcSEcCtD
Nalidixic Acid—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00794	0.00794	CcSEcCtD
Nalidixic Acid—Diplopia—Carmustine—lymphatic system cancer	0.00776	0.00776	CcSEcCtD
Nalidixic Acid—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00746	0.00746	CcSEcCtD
Nalidixic Acid—Leukopenia—Teniposide—lymphatic system cancer	0.00744	0.00744	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Nalidixic Acid—Leukopenia—Fludarabine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Nalidixic Acid—Pruritus—Mechlorethamine—lymphatic system cancer	0.00651	0.00651	CcSEcCtD
Nalidixic Acid—Convulsion—Fludarabine—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Nalidixic Acid—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Nalidixic Acid—Arthralgia—Fludarabine—lymphatic system cancer	0.00622	0.00622	CcSEcCtD
Nalidixic Acid—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Nalidixic Acid—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Nalidixic Acid—Vomiting—Mechlorethamine—lymphatic system cancer	0.00585	0.00585	CcSEcCtD
Nalidixic Acid—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00585	0.00585	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00584	0.00584	CcSEcCtD
Nalidixic Acid—Rash—Mechlorethamine—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Nalidixic Acid—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Nalidixic Acid—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Nalidixic Acid—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Nalidixic Acid—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Nalidixic Acid—Nausea—Mechlorethamine—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Nalidixic Acid—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Nalidixic Acid—Urticaria—Teniposide—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Nalidixic Acid—Abdominal pain—Teniposide—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Nalidixic Acid—Erythema—Bleomycin—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Nalidixic Acid—Paraesthesia—Fludarabine—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Nalidixic Acid—Visual impairment—Carmustine—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Nalidixic Acid—Asthenia—Teniposide—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Nalidixic Acid—Pruritus—Teniposide—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Nalidixic Acid—Leukopenia—Bleomycin—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Nalidixic Acid—Erythema—Carmustine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Nalidixic Acid—Diarrhoea—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Nalidixic Acid—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Nalidixic Acid—Erythema—Mitoxantrone—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Nalidixic Acid—Vomiting—Teniposide—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Nalidixic Acid—Asthenia—Fludarabine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Nalidixic Acid—Rash—Teniposide—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Nalidixic Acid—Dermatitis—Teniposide—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Nalidixic Acid—Headache—Teniposide—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Nalidixic Acid—Pruritus—Fludarabine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Nalidixic Acid—Leukopenia—Carmustine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Nalidixic Acid—Diarrhoea—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Nalidixic Acid—Convulsion—Carmustine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Nalidixic Acid—Nausea—Teniposide—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Nalidixic Acid—Vertigo—Vincristine—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Nalidixic Acid—Leukopenia—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Nalidixic Acid—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Nalidixic Acid—Paraesthesia—Bleomycin—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Nalidixic Acid—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Nalidixic Acid—Convulsion—Vincristine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Nalidixic Acid—Vomiting—Fludarabine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Nalidixic Acid—Convulsion—Mitoxantrone—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Nalidixic Acid—Rash—Fludarabine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Nalidixic Acid—Dermatitis—Fludarabine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Nalidixic Acid—Headache—Fludarabine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Nalidixic Acid—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Nalidixic Acid—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Nalidixic Acid—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Nalidixic Acid—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Nalidixic Acid—Nausea—Fludarabine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Nalidixic Acid—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Nalidixic Acid—Urticaria—Bleomycin—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Nalidixic Acid—Paraesthesia—Carmustine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Nalidixic Acid—Somnolence—Carmustine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Nalidixic Acid—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Nalidixic Acid—Paraesthesia—Vincristine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Nalidixic Acid—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Nalidixic Acid—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Nalidixic Acid—Somnolence—Mitoxantrone—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Nalidixic Acid—Asthenia—Bleomycin—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Nalidixic Acid—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Nalidixic Acid—Pruritus—Bleomycin—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Nalidixic Acid—Eosinophilia—Methotrexate—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Nalidixic Acid—Abdominal pain—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Nalidixic Acid—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Nalidixic Acid—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Nalidixic Acid—Abdominal pain—Vincristine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Nalidixic Acid—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Nalidixic Acid—Urticaria—Mitoxantrone—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Nalidixic Acid—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Nalidixic Acid—Vomiting—Bleomycin—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Nalidixic Acid—Drowsiness—Methotrexate—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Nalidixic Acid—Rash—Bleomycin—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Nalidixic Acid—Dermatitis—Bleomycin—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Nalidixic Acid—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Nalidixic Acid—Asthenia—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Nalidixic Acid—Asthenia—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Nalidixic Acid—Diarrhoea—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Nalidixic Acid—Nausea—Bleomycin—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Nalidixic Acid—Asthenia—Mitoxantrone—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Nalidixic Acid—Dizziness—Carmustine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Nalidixic Acid—Diarrhoea—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Nalidixic Acid—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Nalidixic Acid—Vomiting—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Nalidixic Acid—Dizziness—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Nalidixic Acid—Rash—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Nalidixic Acid—Dermatitis—Carmustine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Nalidixic Acid—Visual impairment—Methotrexate—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Nalidixic Acid—Headache—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Nalidixic Acid—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Nalidixic Acid—Vomiting—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Nalidixic Acid—Rash—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Nalidixic Acid—Dermatitis—Vincristine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Nalidixic Acid—Headache—Vincristine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Nalidixic Acid—Nausea—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Nalidixic Acid—Vomiting—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Nalidixic Acid—Rash—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Nalidixic Acid—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Nalidixic Acid—Headache—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Nalidixic Acid—Erythema—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Nalidixic Acid—Nausea—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Nalidixic Acid—Nausea—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Nalidixic Acid—Vertigo—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Nalidixic Acid—Leukopenia—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Nalidixic Acid—Convulsion—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Nalidixic Acid—Arthralgia—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Nalidixic Acid—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Nalidixic Acid—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Nalidixic Acid—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Nalidixic Acid—Paraesthesia—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Nalidixic Acid—Somnolence—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Nalidixic Acid—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Nalidixic Acid—Urticaria—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Nalidixic Acid—Abdominal pain—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Nalidixic Acid—Asthenia—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Nalidixic Acid—Pruritus—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Nalidixic Acid—Diarrhoea—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Nalidixic Acid—Dizziness—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Nalidixic Acid—Vomiting—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Nalidixic Acid—Rash—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Nalidixic Acid—Dermatitis—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Nalidixic Acid—Headache—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Nalidixic Acid—Nausea—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
